Asia/Oceania
Craif Raises $22M in Series C Round to Expand US, Japan Operations
The Nagoya University spinout will open an office in San Diego and is working toward FDA approval of its miSignal early cancer detection test.
In Brief This Week: 23andMe, OS Therapies, Zai Lab, Genetic Alliance, Galatea Bio, Mursla Bio
News items for the week of April 21, 2025.
Guardant Health, Pfizer Partner to Use Liquid Biopsy to Aid Cancer Therapy Development
Pfizer intends to use Guardant's blood-based tests in global clinical trials, with specific plans to evaluate the clinical utility of its Reveal assay as clinical trial surrogate endpoint.
Akoya, Singapore Consortium Collaborate to ID Markers of Response to Checkpoint Inhibitor Therapy
The project will use Akoya's PhenoCode Discovery IO60 Panel to look at matched pairs of immuno-oncology exceptional responders and hyper-progressors.
Ono Pharmaceutical Taps Jorna Therapeutics for RNA-Editing Drug Discovery Partnership
Ono has an exclusive option to discover, develop, and commercialize drug candidates based on RNA-editing drug sequences designed by Jorna.